Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells
AssigneeMerck Patent GmbH
InventorsValerie Autier, Annick Arbellot De Vacqueur, Micheline Kergoat, Gerard Moinet, Dominique Marais, Catherine Kargar
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of at least one compound with inhibitory activity on kynurenine 3-hydroxylase, for the preparation of a medica ment for increasing the number of islets of Langerhans cells, which is intended especially for the prevention and/or treatment of diabetes.
Claims35
Use of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament for increasing the number of islets of Langerhans cells.
Use of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament for the treatment of prediabetes.
Use of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament for the the treatment and/or prevention of insulin-dependent diabetes.
Use of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament for the prevention of non-insulin-dependent diabetes.
Use of a kynurenine 3-hydroxylase inhibitor for the manufacture of a medicament for the treatment of early non-insulin-dependent diabetes.
Use of a kynurenine 3-hydroxylase inhibitor in combination with one or more immunosuppressants, for the manufacture of a medicament for the prevention and/or treatment of insulin-dependent diabetes.
Process for increasing the number or the insulin-secreting capacity of islets of Langerhans cells, comprising the in vitro application of a kynurenine 3-hydroxylase inhibitor to the said cells.
Pharmaceutical composition comprising a kynurenine 3-hydroxylase inhibitor in combination with one or more immunosuppressants.
31-32. (canceled)
34-52. (canceled)
Dependencies are inferred from the claim text.